Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity. [electronic resource]
Producer: 20210420Description: 458-475 p. digitalISSN:- 1472-8206
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- genetics
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- chemistry
- Breast Neoplasms -- drug therapy
- Carcinoma, Ehrlich Tumor -- drug therapy
- Cardiotoxicity
- Caspase 3 -- metabolism
- Drug Carriers
- Drug Compounding
- Female
- Heart Diseases -- chemically induced
- Humans
- Imatinib Mesylate -- chemistry
- Indoles -- chemistry
- Ki-67 Antigen -- metabolism
- MCF-7 Cells
- Mice
- Nanoparticles
- Polylactic Acid-Polyglycolic Acid Copolymer -- chemistry
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Signal Transduction
- Sulfonamides -- chemistry
- Tumor Burden -- drug effects
- bcl-2-Associated X Protein -- metabolism
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.